Herpes News and Research RSS Feed - Herpes News and Research

Herpes is an infection caused by two different but closely related viruses — herpes simplex virus type 1 (HSV-1) or cold sores and herpes simplex virus type 2 (HSV-2) or genital herpes. Both are easy to catch. They have similar symptoms (blisters or sores) and both can occur on different parts of the body. When the infection is on the mouth, it is called oral herpes. When it is on or near the sex organs, it is called genital herpes. There is no cure for herpes. Treatments are available to speed up the healing of the genital sores.
Researchers examine association between ritual circumcision procedure and HSV-1 in infants

Researchers examine association between ritual circumcision procedure and HSV-1 in infants

A rare procedure occasionally performed during Jewish circumcisions that involves direct oral suction is a likely source of herpes simplex virus type 1 (HSV-1) transmissions documented in infants between 1988 and 2012, a literature review conducted by Penn Medicine researchers and published online in the Journal of the Pediatric Infectious Disease Society found. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]
Ralphs Pharmacies continue to offer Tdap vaccinations for whooping cough in Southern California

Ralphs Pharmacies continue to offer Tdap vaccinations for whooping cough in Southern California

As the number of pertussis cases, also known as whooping cough, reaches epidemic proportions in California, Ralphs Pharmacies continue to offer Tdap (tetanus, diphtheria, pertussis) vaccinations at its 85 in-store pharmacies throughout Southern California. [More]
Interactions with other infections can trigger herpes virus to reactivate, shows research

Interactions with other infections can trigger herpes virus to reactivate, shows research

The famous slogan is "A diamond is forever," but that phrase might be better suited to herpes: Unlike most viruses, which succumb to the immune system's attack, herpes remains in the body forever, lying in wait, sometimes reactivating years later. [More]
Researchers discover analgesic mechanism that prevents pain in Buruli ulcer patients

Researchers discover analgesic mechanism that prevents pain in Buruli ulcer patients

When the body receives an injury to the skin, a signal is sent to the brain, which generates a sensation of pain. [More]
Melanoma in adulthood can be reduced by consistent use of sunscreen in childhood

Melanoma in adulthood can be reduced by consistent use of sunscreen in childhood

Research conducted at the Texas Biomedical Research Institute, published in the latest issue of the scientific journal Pigment Cell and Melanoma, has established unequivocally in a natural animal model that the incidence of malignant melanoma in adulthood can be dramatically reduced by the consistent use of sunscreen in infancy and childhood. [More]
Human herpes simplex virus infected human approximately 1.6 million years ago

Human herpes simplex virus infected human approximately 1.6 million years ago

Researchers at the University of California, San Diego School of Medicine have identified the evolutionary origins of human herpes simplex virus (HSV) -1 and -2, reporting that the former infected hominids before their evolutionary split from chimpanzees 6 million years ago while the latter jumped from ancient chimpanzees to ancestors of modern humans - Homo erectus - approximately 1.6 million years ago. [More]
PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections. [More]
Scientists unravel how herpesviruses fight against our immune system

Scientists unravel how herpesviruses fight against our immune system

How the virus does this was unknown until now. The scientists from the HZI research group "Viral Immune Modulation" under the leadership of Prof. Melanie Brinkmann have now been able to show that the virus is actively preventing activation of the innate immune system through Toll-like receptors. [More]
High dose vitamin C therapy may have positive effect on Epstein-Barr virus infection

High dose vitamin C therapy may have positive effect on Epstein-Barr virus infection

The Epstein-Barr virus (EBV) is a member of the herpes family that targets lymphocytes and epithelial cells. While the infection is usually benign, it can in some cases lead to acute infectious mononucleosis and can impair the immune system. EBV is also linked to several malignancies. There is currently no cure for removing EBV infections and very little success treating acute EBV infection and mononucleosis with drugs. [More]
HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

More than a quarter of HIV+ patients are also infected with the Hepatitis C virus (HCV), which may complicate treatment and care decisions after a cancer diagnosis. The specifics of those complications haven't been well-researched in the past. Results from a new Fox Chase Cancer Center study on this patient population may start filling in that gap. [More]
Researchers develop new method for isolating, genome sequencing individual malaria parasite cell

Researchers develop new method for isolating, genome sequencing individual malaria parasite cell

A new method for isolating and genome sequencing an individual malaria parasite cell has been developed by Texas Biomed researchers in San Antonio and their colleagues. [More]
Nanoviricides develops new drug candidates against MERS infection

Nanoviricides develops new drug candidates against MERS infection

... [More]
UAMS receives $1.8M grant to lead new treatments for herpes viruses and cancers

UAMS receives $1.8M grant to lead new treatments for herpes viruses and cancers

A surprise discovery that could lead to new treatments for herpes viruses that infect more than 90 percent of the world's adult population has led to a $1.8 million grant to the University of Arkansas for Medical Sciences (UAMS) from the National Cancer Institute (NCI) at the National Institutes of Health (NIH). [More]
Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. [More]
FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

The US Food and Drug Administration has announced the expanded approval of Arzerra (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra. [More]
Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate. [More]
Scientists develop microbicide gel that prevents transmission of multiple STIs in vagina/rectum in animals

Scientists develop microbicide gel that prevents transmission of multiple STIs in vagina/rectum in animals

Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections (STIs) in both the vagina and rectum in animals: HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). [More]
Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%. [More]
Herpes simplex viral therapy in conjunction with radiation proves effective in treating malignant gliomas

Herpes simplex viral therapy in conjunction with radiation proves effective in treating malignant gliomas

Researchers at the University of Alabama at Birmingham report a genetically engineered herpes simplex viral therapy is safe when used in conjunction with radiation in the treatment of malignant gliomas, one of the most deadly forms of brain cancer. [More]